Methylene Blue is a prescription therapy used for mitochondrial support and cognitive function.

Patients seeking support for mitochondrial support and cognitive function may qualify after evaluation by a licensed provider.

Yes. Methylene Blue is a compounded prescription medication dispensed pursuant to a valid prescription from a licensed healthcare provider. A telehealth consultation and medical intake are required before dispensing to ensure the formulation is appropriate for your health history, goals, and current medications. All eligibility is reviewed by a licensed medical professional.

At prescribed doses, Methylene Blue is generally well tolerated. The most predictable and expected effect is temporary blue-green discoloration of urine — this is harmless and resolves when dosing is paused or stopped. Some patients report mild nausea or headache during initial use. Methylene Blue exerts mild MAO-inhibiting activity at higher doses; patients sensitive to monoamine-related effects should report any unusual mood changes, agitation, or neurological symptoms to their provider promptly. As with any prescription compound, individual responses vary.

Methylene Blue is contraindicated in patients with G6PD (glucose-6-phosphate dehydrogenase) deficiency, as it can trigger hemolytic anemia in this population. Patients taking serotonergic medications — including SSRIs, SNRIs, MAOIs, or tricyclic antidepressants — should not use Methylene Blue without explicit specialist guidance, due to the risk of serotonin syndrome. It is not appropriate for patients with severe renal or hepatic impairment, those who are pregnant or breastfeeding, or patients under 18. Disclose your complete medication list to your provider before starting.

Methylene Blue's most clinically significant interaction is with serotonergic medications. Co-administration with SSRIs, SNRIs, MAOIs, tricyclic antidepressants, or other drugs that raise serotonin activity carries a risk of serotonin syndrome — a potentially serious and life-threatening reaction. In most cases this combination results in Methylene Blue not being prescribed until serotonergic medications have been discontinued and appropriate washout has occurred. Patients on anticoagulants, antidiabetic agents, or cardiac medications should also disclose these before starting, as Methylene Blue's complex redox and MAO activity may interact with their pharmacodynamics. Always provide a complete medication list before beginning treatment.

Patients with G6PD deficiency must not use this compound. Those with a history of cardiac arrhythmia, significant renal or hepatic impairment, or documented sensitivity to methylene-based dyes require individualized provider evaluation. Patients with any personal or family history of malignancy should disclose this, as Methylene Blue has complex mitochondrial and redox activity. Your provider requires a complete medical history before prescribing and will determine whether Methylene Blue is appropriate given your individual health profile.